Literature DB >> 8405013

Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes.

K Chiba1, K Manabe, K Kobayashi, Y Takayama, M Tani, T Ishizaki.   

Abstract

We have developed a simple HPLC assay to measure the activity of S-mephenytoin 4-hydroxylase in human liver microsomes, and have assessed its practical applicability by determining the kinetic parameters of the enzyme in 10 different human liver samples. The recovery of 4-hydroxymephenytoin and phenobarbital (the internal standard) after the precipitation of microsomal protein was almost complete, and the coefficients of variation for the intra- and interassay measurement of S-mephenytoin 4-hydroxylase activity were < 6.4 and 8.0%, respectively. Eadie-Hofstee plots for the formation of 4-hydroxymephenytoin gave a straight line for all of the 10 samples studied. There was large interindividual variability in the kinetic parameters estimated: 4.6- (36 to 166 microM), 11.8- (0.9 to 10.6 nmole/mg protein/h) and 30.1- times (0.10 to 3.01 microliters/mg protein/min) for Km, Vmax and Vmax/Km, respectively. The mean (+/- SD) Km, Vmax and Vmax/Km were 72.4 +/- 40.4 microM, 4.23 +/- 2.88 nmole/mg protein/h and 1.33 +/- 1.02 microliters/mg protein/min, respectively. Thus, the assay was sufficiently accurate and reproducible to permit estimation of the kinetic parameters of S-mephenytoin 4-hydroxylase in human liver microsomes, and it appears to be applicable to an in vitro study of the possible involvement of S-mephenytoin-type oxidation polymorphism in drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405013     DOI: 10.1007/bf02440859

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.

Authors:  T Yasumori; N Murayama; Y Yamazoe; R Kato
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

Review 2.  Human drug metabolism in vitro.

Authors:  P H Beaune; F P Guengerich
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

3.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

4.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography.

Authors:  U T Meier; T Kronbach; U A Meyer
Journal:  Anal Biochem       Date:  1985-12       Impact factor: 3.365

6.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

7.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

Authors:  L Bertilsson; T K Henthorn; E Sanz; G Tybring; J Säwe; T Villén
Journal:  Clin Pharmacol Ther       Date:  1989-04       Impact factor: 6.875

8.  Mephenytoin metabolism in vitro by human liver.

Authors:  M Jurima; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Mar-Apr       Impact factor: 3.922

9.  Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

Authors:  D R Sohn; M Kusaka; T Ishizaki; S G Shin; I J Jang; J G Shin; K Chiba
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

10.  Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.

Authors:  S D Hall; F P Guengerich; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

View more
  5 in total

1.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

2.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

Authors:  K Chiba; A Saitoh; E Koyama; M Tani; M Hayashi; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

4.  Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.

Authors:  Mahnaz Salsali; Andrew Holt; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

5.  In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong.

Authors:  Hui Chen; Ya Zhang; Xiaoying Wu; Candong Li; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.